MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
shares, net of issuance...
$10,725K
Proceeds from issuance of
notes payable
$2,099K
Proceeds from issuance of
warrants
$1,036K
Proceeds from pre-funded
warrants
$330K
Proceeds from employee
vesting of restricted...
$33K
Net cash provided by
financing activities
$13,171K
Effect of exchange
rates on cash
$1K
Canceled cashflow
$1,052K
Net change in cash
$2,604K
Canceled cashflow
$10,568K
Repayment of notes payable
and convertible...
$553K
Payments on
seller-financed purchases
$499K
Impairment loss on other
intangible assets
$5,180K
Loss on debt
extinguishment
-$3,164K
Stock-based compensation
$2,890K
Prepaid expenses and
other current assets
-$594K
Accretion of debt issuance
costs
$589K
Loss on derivative
liability
-$230K
Issuance of shares for
services
$27K
Net cash used in
operating activities
-$10,568K
Canceled cashflow
$12,674K
Net loss
-$17,298K
Gain on settlement of
current liabilities
$2,984K
Deferred income tax
benefit
-$1,088K
Accounts payable and
accrued expenses
-$998K
Change in fair value of
warrant liabilities
$775K
Unrealized foreign
currency exchange losses...
$99K
Back
Back
Cash Flow
source: myfinsight.com
Akari Therapeutics Plc (AKTX)
Akari Therapeutics Plc (AKTX)